Research across Cancer
Related studies from across the Cancer family.
Ultrasound-guided salvage brachytherapy with interstitial hyperthermia shows low toxicity in locally recurrent prostate cancer
New prostate cancer treatment shows low side effects after 5 years
This prospective phase 2 trial evaluated ultrasound-guided salvage brachytherapy with interstitial hyperthermia in 109 patients with locally…
A new treatment for recurrent prostate cancer kept 93% of patients alive at 5 years with very low serious side effects.
Meta-analysis shows percutaneous irreversible electroporation plus immunotherapy improves outcomes in locally advanced pancreatic cancer
Adding immunotherapy to ablation therapy extends life for pancreatic cancer patients
This systematic review and meta-analysis evaluated percutaneous irreversible electroporation combined with immunotherapy versus irreversible…
Adding immune therapy to ablation therapy helps patients live longer with locally advanced pancreatic cancer without causing more side effec…
Retrospective review finds higher ORR with salvage DCRT in locally advanced ESCC
Salvage therapy works better than upfront treatment for some esophageal cancer patients
This retrospective analysis of 91 patients from 3 medical centers compared salvage versus upfront definitive chemoradiotherapy (DCRT) for lo…
New data shows treating esophageal cancer after a failed first attempt may lead to better outcomes than starting with the strongest drugs im…
Systematic review finds neoadjuvant chemohormonal therapy improves biochemical progression-free survival in locally advanced prostate cancer
Chemo Before Prostate Surgery Linked to Better Cancer Control
This systematic review and meta-analysis evaluated neoadjuvant chemohormonal therapy (NCHT) combined with radical prostatectomy versus radic…
Patients with advanced prostate cancer may see better cancer control with chemo before surgery, though survival gains need more proof.
Hong Kong consensus statement updates management for locally advanced and metastatic renal cell carcinoma
New Kidney Cancer Rules Change How Doctors Treat Metastasis
This guideline presents a consensus statement developed by 6 urologists and 8 clinical oncologists in Hong Kong regarding locally advanced a…
New expert rules update kidney cancer care with more drug options and clearer surgery plans.
Review of case report showing durable response after surgery in metastatic bladder SqCC
She Was Offered Hospice. Surgery Gave Her Two More Years Instead
This narrative review synthesizes a single case report of a 65-year-old woman with metastatic squamous cell carcinoma of the bladder.
A woman with a rare, drug-resistant bladder cancer that had spread to both lungs chose surgery when hospice was offered — and two years late…
Curative-intent local therapy linked to improved survival in isolated contralateral axillary breast metastasis
Local therapy linked to better survival in advanced breast cancer patients with specific metastases
This retrospective cohort study of 1110 patients across two tertiary centers compared outcomes in isolated contralateral axillary metastasis…
Patients with specific breast cancer spread to the opposite armpit survived longer when receiving surgery or radiation compared to systemic …
SABR shows 46% 5-year overall survival in unfit NSCLC patients in phase 2 trial
Precision Radiation Offers a Real Option for Lung Cancer Patients Who Can't Do Chemo
A non-randomized phase 2 trial of 50 patients with unresectable locally advanced NSCLC unfit for concurrent chemoradiation found 5-year over…
Nearly half of patients treated with precision radiation were still alive at five years, offering hope for lung cancer patients too frail fo…
Optimal Pathological Response in LACC After Neoadjuvant Chemoimmunotherapy Shows Promising Short-Term Survival
Good news for advanced cervical cancer patients
A retrospective real-world analysis of 89 patients with locally advanced cervical cancer treated with neoadjuvant chemoimmunotherapy and rad…
Women with advanced cervical cancer who respond well to initial treatment show over 90% survival and may avoid harsh follow-up drugs.
Encorafenib plus binimetinib maintains quality of life in BRAF V600E-mutated thyroid cancer
Can new drugs help advanced thyroid cancer patients keep their daily life stable?
An uncontrolled phase 2 trial of 22 patients with BRAF V600E-mutated thyroid cancer found encorafenib plus binimetinib was associated with g…
A new drug combination helped advanced thyroid cancer patients maintain daily life stability without worsening their quality of life during …
Intratumoral H101 plus total neoadjuvant therapy yields pathologic complete response in one patient with metachronous locally advanced rectal cancer
Could a virus help save a patient's rectal cancer and their ability to use the bathroom?
This case report describes a 50-year-old patient with metachronous locally advanced rectal cancer treated with intratumoral injection of rec…
A virus combined with standard therapy helped a 50-year-old man clear his rectal cancer while keeping his bowel control intact.
Feasibility study fails to meet recruitment target for HDR brachytherapy vs SBRT in recurrent prostate cancer
Why is it so hard to recruit men for a second prostate cancer radiation study?
A 3-center randomized feasibility study of 23 patients with locally recurrent prostate cancer found planned recruitment targets were not met…
Men refused to let chance decide their second prostate cancer radiation treatment, causing a major study to fall far short of its recruitmen…